![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1430563
¼¼°èÀÇ ·¦ ÀÎÆ÷¸Åƽ½º : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå µ¿Çâ ¿¹Ãø(2024-2029³â)Global Laboratory Informatics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) |
¼¼°èÀÇ ·¦ ÀÎÆ÷¸Åƽ½º ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 38¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â¿¡´Â 57¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß(2024-2029³â) CAGRÀº 8.31%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
Áõ°Çö½Ç(AR), ÀΰøÁö´É(AI), °¡»óÇö½Ç(VR) ¼Ö·ç¼ÇÀº COVID-19 ÆÒµ¥¹Í¿¡ ´ëÀÀÇϰí Áö¼ÓÀûÀ¸·Î ÁøÈÇÏ´Â °úÁ¦¿¡ ´ëÀÀÇÏ´Â µ¥ Å« ±â¿©¸¦ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À̹ø ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ Á¦¾à¾÷ü¿Í ÀÇ·á ±â°üÀº AI¿¡ ´ëÇÑ R&D ÅõÀÚ¸¦ °ÈÇÏ¿© ´Ù¾çÇÑ ±¸»óÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ÇÙ½É ±â¼ú·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
COVID-19·Î ÀÎÇØ Á¤ºÎ¿Í ±â°üµéÀÌ COVID-19 ¹é½ÅÀ» °³¹ß ¹× Ãâ½ÃÇÏ¿© ÁßÁõµµ Áõ°¡¸¦ ¾ïÁ¦Çϱâ À§ÇØ COVID-19 ¹é½ÅÀ» °³¹ß ¹× Ãâ½ÃÇØ¾ß ÇÏ´Â »óȲ¿¡¼ COVID-19´Â ½ÃÀå¿¡ °¡Àå Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. µû¶ó¼ ÃÖÀûÈµÈ Á¢±Ù ¹æ½Ä¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÇ ICH-Good Clinical Practice R2´Â ÀÓ»ó ÀǾàǰ °³¹ß, ½Å¼ÓÇÑ ÃßÀû ¹× ½ÃÇè Áß À§Çè ¸ð´ÏÅ͸µ¿¡ µû¶ó °³Á¤µÇ¾úÀ¸¸ç, ÀÌ´Â COVID-19 ÀǾàǰÀÇ °³¹ß ÇöȲÀ» ÃßÀûÇÏ´Â µ¥ Áß¿äÇÑ ÅøÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¶ÇÇÑ ³ôÀº °á°úÀÇ Á¤È®¼º°ú È¿À²¼º, ½ÇÇè½Ç Á¤º¸ÇÐ ¼Ö·ç¼ÇÀÇ Àû¿ë Áõ°¡, Áø´Ü °Ç¼ö Áõ°¡ µîÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.
ÀÛ¾÷·® Áõ°¡, ºñ¿ë Á¦¾à ¹× ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ º´¸® °Ë»çÀÇ Æ¯¼ºÀº ½ÃÀåÀÇ ¿ä±¸¿¡ µû¶ó ºü¸£°Ô º¯ÈÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î °Ë»ç ½Ã½ºÅÛÀº ÇöÀç ¼¼°è ¼ö¿ä¸¦ ¿ÏÈÇϱâ À§ÇØ ÃÖ°íÀÇ ±â¼ú·Î Á¦Á¶µÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÇ º¯ÈÇÏ´Â ¿ä±¸ »çÇ×À» ÃæÁ·½Ã۱â À§ÇØ °Ë»ç Á¤º¸¸¦ °ü¸®ÇÏ´Â »õ·Î¿î Á¢±Ù ¹æ½ÄÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÓ»óÀÇÀÇ °¡Àå Å« °ü½É»ç´Â ´Ù¾çÇÑ Ãâó¿¡¼ ¾òÀº Á¤º¸ÀÇ Á¤È®¼ºÀÔ´Ï´Ù. ±×·¯³ª 2020³â 3¿ù¿¡ ¹ßÇ¥µÈ ³í¹® 'Making Healthcare Safer III: A Critical Analysis of Existing and Emerging Patient Safety Practices'¿¡ µû¸£¸é Áø´Ü ¿À·ùÀÇ À¯º´·üÀº ¿Ü·¡ ȯÀÚ¿¡¼ 5%, ÀÔ¿ø ȯÀÚ¿¡¼ 6%·Î ³ªÅ¸³µ½À´Ï´Ù. ¼ºÀÎÀÇ °æ¿ì 5%, ÀÔ¿øÀÇ °æ¿ì 6-17%ÀÔ´Ï´Ù. µû¶ó¼ ÀÌ·¯ÇÑ Áø´Ü ¿À·ù¸¦ ¹æÁöÇÏ°í ´õ ³ªÀº ¼ºñ½º¸¦ Á¦°øÇϱâ À§ÇØ Áø·á¼Ò¿Í °Ë»ç½ÇÀº °Ë»ç Á¤º¸ ½Ã½ºÅÛ(LIS)À̳ª LIMS¿Í °°Àº ´Ù¾çÇÑ ÅøÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½ÇÇè½Ç ÀÎÆ÷¸Åƽ½º´Â Abbott HealthcareÀÇ LIMS Ç÷§Æû STARLIMS¿Í °°ÀÌ »ç¿ëÀÚ ÀÎÅÍÆäÀ̽º Ãø¸é¿¡¼ À¯¿¬¼ºÀ» Á¦°øÇϸç, ÀÌ·¯ÇÑ ÅøÀÇ µµ¿òÀ¸·Î ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀ» ÅëÇØ Á¶ÀÛÇÒ ¼ö ÀÖÀ¸¸ç, Áø´Ü °Ë»ç¸¦ Æ÷ÇÔÇÑ ½ÇÇè½Ç ¾÷¹«°¡ ÈξÀ ½¬¿öÁ³½À´Ï´Ù. ½ÇÇè½Ç µ¥ÀÌÅÍ °ü¸® ¹× ½ÇÇè½Ç ¿öÅ© Ç÷οì ÁøÇàÀº ½ÇÇè½Ç Á¤º¸ÇÐ ÅøÀÇ µµ¿òÀ¸·Î ´Þ¼ºµÇ¸ç ³ôÀº Á¤È®µµ¸¦ Á¦°øÇÕ´Ï´Ù. µû¶ó¼ ½ÇÇè½Ç Á¤º¸ÇÐÀº ±Ã±ØÀûÀ¸·Î ½ÇÇè½ÇÀÇ Àü¹ÝÀûÀÎ È¿À²¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù.
LIMS´Â ¼·Î ´Ù¸¥ ½ÇÇè½ÇÀÇ µ¥ÀÌÅÍ »ùÇøµÀ» °³¼±ÇÏ°í ¿¬±¸ Á¤º¸ ÅëÇÕÀ» Áö¿øÇϸç, 2020³â 7¿ù Gordon fellerÀÇ ±â»ç¿¡ µû¸£¸é SciCordÀÇ ÀüÀÚ¿¬±¸³ëÆ®(ELN)(ELN)/LIMS ¼Ö·ç¼ÇÀº Á¾ÀÌ ³ëÆ®¸¦ ´ëüÇÒ ¼ö ÀÖ´Â µðÁöÅÐ ´ë¾ÈÀ¸·Î 6,000¸íÀÇ °úÇÐÀÚµéÀÌ Ã¤ÅÃÇÏ¿© »ý»ê¼ºÀ» 30% Çâ»ó½ÃÄ×´Ù°í ÇÕ´Ï´Ù. 6,000¸í ÀÌ»óÀÇ °úÇÐÀÚµéÀÌ Ã¤ÅÃÇßÀ¸¸ç, äÅÃÀ¸·Î ÀÎÇØ »ý»ê¼ºÀÌ 30% Çâ»óµÇ¾ú´Ù°í º¸°íµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ÀÓ»óÀÇ¿Í º´¸®ÇÐÀÚµéÀÌ ÃÖ»óÀÇ °á°ú¿Í ¿À·ù ¾ø´Â °á°ú¸¦ Á¦°øÇÏ·Á´Â ³ë·ÂÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÇÇè½Ç Á¤º¸È Á¦Ç° ¹× ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
±×·¯³ª ½ÇÇè½Ç Á¤º¸È¿¡ ´ëÇÑ ÅëÇÕ Ç¥ÁØÀÇ ºÎÀç¿Í ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·À¸·Î ÀÎÇØ Àüü ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.
COVID-19´Â ÆÒµ¥¹Í »óȲ¿¡ ´ëÀÀÇϱâ À§ÇØ ½Ã°£°ú ±â¼ú Çõ½ÅÀ» °í·ÁÇÑ °Ë»ç ÀýÂ÷¿¡ ´ëÇÑ ¾Ð¹ÚÀ» °¡Áß½Ã۰í ÀÖ½À´Ï´Ù. µû¶ó¼ ±âÁ¸ÀÇ °Ë»ç½Ç ÀýÂ÷´Â Àüü ¾÷¹« °ü¸® Ãø¸é¿¡¼ ¾÷±×·¹À̵尡 ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â LIMS¿¡ ´ëÇÑ ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö Àִµ¥, LIMS´Â °á°ú º¸°í ±â´ÉÀ» ÅëÇØ FDAÀÇ ±ÔÁ¦ ¿öÅ©Ç÷ο쿡¼ ½Å¼ÓÇÑ ½ÂÀÎÀ» ¹ÞÀ» ¼ö ÀÖ´Â °¡´É¼ºÀ» º¸¿©ÁÖ°í ÀÖÀ¸¸ç, FDA¿Í CDCÀÇ °¡À̵å¶óÀο¡ µû¶ó CloudLIMS´Â ÀÌ¹Ì FDA ½ÂÀÎÀ» ¹ÞÀº »çÀü ¼³Á¤µÈ ¿öÅ©Ç÷ο츦 »ç¿ëÇÏ¿© ÀÌ¹Ì ¿©·¯ ½ÇÇè½ÇÀ» 1ÁÖÀÏ À̳»¿¡ Áö¿øÇÑ ¹Ù ÀÖ½À´Ï´Ù.
Àü ¼¼°è¿¡¼ À¯ÇàÇÏ´Â ÆÒµ¥¹Í »óȲ¿¡¼´Â Áõ°¡ÇÏ´Â È®ÁøÀÚ¸¦ ÅëÁ¦ÇÏ´Â µ¥ ½Ã°£ÀÌ Áß¿äÇÑ ¿ä¼ÒÀ̱⠶§¹®¿¡ LIMS Ç÷§ÆûÀº ½ÇÇè½Ç Á¤º¸¸¦ ÃßÀûÇÏ°í ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â °·ÂÇÑ Ç÷§ÆûÀ¸·Î, Lab Advantage Solutions¿Í °°Àº ȸ»ç´Â LabVantage COVID-19 LIMS¸¦ °³¹ßÇß½À´Ï´Ù. ÀÌ Ç÷§ÆûÀº ³»ÀåµÈ ±â´ÉÀ» ÅëÇØ 4ÁÖ À̳»¿¡ ½ÇÇè½Ç ¿öÅ©Ç÷ο츦 °ü¸®ÇÏ°í °¡¼ÓÈÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
¶ÇÇÑ °Ë»ç Á¤º¸ÇÐ ½ÃÀåÀÇ Á¦Ç° ºÎ¹®¿¡¼´Â °Ë»ç Á¤º¸ °ü¸® ½Ã½ºÅÛÀÌ °¡Àå Å« ½ÃÀå ±Ô¸ð¸¦ °¡Áø °ÍÀ¸·Î °£Áֵ˴ϴÙ.
½ÇÇè½Ç Á¤º¸ ½Ã½ºÅÛ(LIMS)Àº ½Ã·áÀÇ È帧°ú °ü·Ã µ¥ÀÌÅ͸¦ È¿À²ÀûÀ¸·Î °ü¸®ÇÏ¿© ½ÇÇè½ÇÀÇ È¿À²¼ºÀ» Çâ»ó½Ã۰í, LIMS´Â ÀϹÝÀûÀ¸·Î ǰÁú °ü¸® ½ÇÇè½Ç°ú °°ÀÌ ¹Ýº¹ÀûÀÎ ¿öÅ©Ç÷ο츦 °¡Áø ½ÇÇè½ÇÀ» ´ë»óÀ¸·Î Çϸç, LIM ½Ã½ºÅÛ¿¡´Â Ư¼öÇÑ µ¥ÀÌÅÍ ±¸Á¶°¡ Æ÷ÇԵǾî ÀÖ°í, ½ÇÇè½Ç ÇÁ·Î¼¼½º(¿öÅ©Ç÷οì)°¡ ÀÌ¹Ì ÀÏÁ¤ÇÑ Çü½ÄÀ¸·Î È®¸³µÇ¾î ÀÖ¾î¾ß ÇÕ´Ï´Ù. LIMS Á¦Ç°Àº ÃÖ±Ù ¼ö³â°£ ÀüÀÚ¿¬±¸³ëÆ®(ELN)(ELN) ¹× ½ÇÇè ½ÇÇà ½Ã½ºÅÛ(LES)¿¡ ÀÇÇØ Á¡À¯À²À» »©¾Ñ±â°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â LES º¥´õÀÇ ¸ÅÃâ Áõ°¡¿Í ÁÖ¿ä LIMS °ø±Þ¾÷üÀÇ ELN ¹× LES ºÐ¾ß ÅõÀÚ¿¡¼ º¼ ¼ö ÀÖÀ¸¸ç, LabVantage Solutions Inc.¿Í °°Àº ½ÃÀå ¼±µµ ±â¾÷Àº Á¾ÇÕÀûÀÌ°í °íµµ·Î ÅëÇÕµÈ LES ¹× ELN ±â´ÉÀ» °³¹ßÇϱâ À§ÇØ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½ÇÇè½Ç ÀÎÆ÷¸Åƽ½º ½Ã½ºÅÛÀ» ¹ÙÀÌ¿À¹ðÅ·¿¡ ÅëÇÕÇÏ´Â °Íµµ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº µ¥ÀÌÅÍ Ç°Áú, ÃÖÁ¾»ç¿ëÀÚ¿¡ ´ëÇÑ Ã»±¸, ȯÀÚ ¼Ó¼º ¹× º¸¾ÈÀ» È¿°úÀûÀ¸·Î °ü¸®Çϰí ÃßÀûÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¿¹¸¦ µé¾î CloudLIMS´Â ¸ñÀû¿¡ ¸Â°Ô ±¸ÃàµÈ È®Àå °¡´ÉÇÑ SaaS Ŭ¶ó¿ìµå LIMS·Î, ÀÚµ¿È, µ¥ÀÌÅÍ °ü¸® ¹× ±ÔÁ¦ ¿ä°ÇÀ» Áö¿øÇÔÀ¸·Î½á ¹ÙÀÌ¿À ¸®Æ÷ÁöÅ丮¿Í ÇÔ²² ¼ºÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¥ÀÌÅÍ »ùÇøµ°ú ¿¬±¸ Á¤º¸ ÅëÇÕÀ» °³¼±ÇÏ°í µ¥ÀÌÅÍ ¾×¼¼½º¸¦ ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. 2020³â 7¿ù, LabVantage Solutions´Â °úÇÐ µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ(SDMS)À» ¿ÏÀüÈ÷ ÅëÇÕÇÑ ½ÇÇè½Ç Á¤º¸ °ü¸® ½Ã½ºÅÛ(LIMS) 8.5 ¿¡µð¼ÇÀ» Ãâ½ÃÇÏ¿© ½ÃÀå ÀÔÁö¸¦ °ÈÇÏ´Â ÇÑÆí, ½ÃÀå Âü¿© ±â¾÷Àº Àü ¼¼°è¿¡¼ »õ·Î¿î LIMS¸¦ Ãâ½ÃÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.À» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÇÇè½Ç Á¤º¸ °ü¸® ½Ã½ºÅÛ ºÎ¹®Àº ½ÃÀå ¼ºÀå¿¡ Å« ±â¿©¸¦ ÇÒ °ÍÀÔ´Ï´Ù.
¹Ì±¹Àº Àü ¼¼°è¿¡¼ COVIDÀÇ ¿µÇâÀ» °¡Àå ¸¹ÀÌ ¹Þ´Â ±¹°¡·Î, COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ´Ù¾çÇÑ Ç÷§Æû ¹× ȯÀÚ¿ÍÀÇ µ¥ÀÌÅÍ °øÀ¯°¡ ÇʼöÀûÀ¸·Î ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Áø´Ü¼¾ÅÍ¿¡¼ º´¿ø, ±×¸®°í ¾ç¼º ÆÇÁ¤À» ¹ÞÀº ȯÀÚ±îÁö µ¥ÀÌÅÍ´Â ÇÁ¶óÀ̹ö½Ã³ª À±¸®Àû Ä¡·á ¹× ¿¬±¸¿¡ ÇʼöÀûÀÎ ´Ù¸¥ ¿ä¼ÒµéÀ» Èñ»ýÇÏÁö ¾Ê°í °¡´ÉÇÑ ÇÑ ÀÚÀ¯·Ó°Ô Èê·¯¾ß ÇÕ´Ï´Ù. µû¶ó¼ ¹Ì±¹¿¡¼´Â ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ µðÁöÅÐ Á¤º¸ ½Ã½ºÅÛ¿¡ ÁßÁ¡À» µÎ¾î ½ÃÇàµÈ ÃÑ °Ë»ç, Ä¡·á °á°ú, ÁøÈÇÏ´Â »ç·Ê Á¤ÀÇ ¹× ±âŸ ¿©·¯ ÇÁ·Î¼¼½ºÀÇ °£¼Òȸ¦ ±â·ÏÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼ COVID-19 ÆÒµ¥¹ÍÀº ÇöÀç¿Í ¹Ì·¡¿¡ °Ë»ç Á¤º¸ ½Ã½ºÅÛÀÇ »ç¿ë°ú äÅÃÀ» Áõ°¡½Ãų °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
ºÏ¹Ì´Â ÇöÀç °Ë»ç Á¤º¸ ½Ã½ºÅÛ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ÇâÈÄ ¼ö³â°£ ±× ÀÚ¸®¸¦ Áöų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº ÇコÄÉ¾î »ê¾÷ÀÌ Àß ¹ß´ÞµÇ¾î ÀÖ°í, ÀÇ·áºñ »óȯ Á¦µµ°¡ Àß °®ÃçÁ® ÀÖÀ¸¸ç, ÇâÈÄ ½ÃÀå Á¡À¯À²ÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹ÀÌ ºÏ¹Ì ½ÃÀåÀÇ ´ëºÎºÐÀ» Â÷ÁöÇϰí ÀÖ´Â ÀÌÀ¯´Â ¹Ì±¹³» µðÁöÅÐ ÇコÄÉ¾î µµÀÔÀÌ È°¹ßÈ÷ ÀÌ·ç¾îÁö°í ÀÖ°í, ¹Ì±¹ ±â¾÷ÀÇ ÅõÀÚ°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.
¶ÇÇÑ ¹Ì±¹¿¡¼´Â ³ëÀÎ Àα¸°¡ ³ôÀº ºñÀ²·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Àα¸´Â ¿©·¯ Áúº´°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. µû¶ó¼ »ýȰ½À°üº´ Áõ°¡´Â °á±¹ °Ëü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÇÇè½Ç ½Ã½ºÅÛÀº È¿À²¼ºÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
¿©·¯ ±â¾÷ÀÌ °Ë»ç Á¤º¸ÇÐ °ü·Ã Á¦Ç°, ¼ºñ½º ¹× ±¸»óÀ» Ãâ½ÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 3¿ù Ovation.io´Â ¹Ì±¹ Àü¿ªÀÇ COVID-19 °Ë»ç ´É·ÂÀ» µÎ ¹è·Î ´Ã¸®´Â ±¸»óÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ±¸»ó¿¡¼ Ovation.io´Â °Ë»ç½ÇÀÌ È¯ÀÚ¿¡°Ô ¼ºñ½º¸¦ Á¦°øÇÏ°í °øÁß º¸°Ç µ¥ÀÌÅ͸¦ ¼öÁýÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â Ŭ¶ó¿ìµå ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. À̸¦ ÅëÇØ ÀÓ»óÀǰ¡ °á°ú¿Í º¸°í¼¿¡ ½Å¼ÓÇÏ°Ô ¾×¼¼½ºÇÏ¿© ½Å¼ÓÇÑ Áø´Ü°ú Ä¡·á¸¦ ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.
½ÇÇè½Ç ÀÎÆ÷¸Åƽ½º ½ÃÀåÀº °æÀïÀÌ Ä¡¿ÇÏ°í ¿©·¯ ´ë±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ½ÃÀå Á¡À¯À² Ãø¸é¿¡¼ º¼ ¶§ ÇöÀç ¼Ò¼öÀÇ ´ë±â¾÷ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç Abbott Laboratories(Abbott Informatics Corporation), Agilent Technologies, McKesson Corporation, Thermo Fischer Scientific Inc. µîÀÌ ½ÃÀå¿¡¼ »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
The Global Laboratory Informatics Market size is estimated at USD 3.82 billion in 2024, and is expected to reach USD 5.77 billion by 2029, growing at a CAGR of 8.31% during the forecast period (2024-2029).
Augmented reality (AR), artificial intelligence (AI), and virtual reality (VR) solutions are anticipated to contribute substantially, while responding to the COVID-19 pandemic and address continuously evolving challenges. Due to the epidemic outbreak, the existing situation may inspire pharmaceutical vendors and healthcare establishments to improve their R&D investments in AI, acting as a core technology for enabling various initiatives.
COVID-19 has the highest impact on the market as the pandemic has forced the government and agencies to develop and launch the COVID-19 vaccine to control the severity in cases. Thus, the demand for an optimized approach example, the United States Food and Drug Administration ICH-Good Clinical Practice R2, has been amended as per clinical drug development and fast-tracking and monitoring risk during trials and found to be an important tool in COVID-19 drug development status tracking.
Moreover, factors driving the market include high accuracy and efficiency of results, increasing applications of lab informatics solutions, and the increasing number of diagnoses.
Owing to the increased workload, cost constraints, and advancements in technologies, the nature of pathology is rapidly changing, as per the need of the market. New laboratory systems are manufactured with the best technologies to alleviate the current global demand. New approaches for managing laboratory information are now required to fulfill the changing requirements of the healthcare system. The primary concern for clinicians is the accuracy of the information that they get through various resources. However, according to an article 'Making Healthcare Safer III: A Critical Analysis of Existing and Emerging Patient Safety Practices' published in March 2020, the prevalence of diagnostic error is 5% in adults being affected in the outpatient environment and 6 to 17% in hospital admission. Thus, to avoid these diagnostic errors and to provide better services, clinics and laboratories are implementing various tools, such as laboratory information systems (LIS) and LIMS.
Moreover, The laboratory information systems provide flexibility in terms of user interface like Abbott Healthcare LIMS platform STARLIMS can be operated through mobile application with the help of such tools, laboratory operations, including the diagnostic tests, have become much easier. The management of the laboratory data and progress in the laboratory workflow is achieved with the help of laboratory informatics tools, and high accuracy is provided. Hence, laboratory informatics ultimately improves the overall efficiency of the laboratories.
The LIMS improves the sampling of data that involves different laboratories and aids in integrating research information. According to an article published by Gorden feller in July 2020, it was reported that SciCord offers an electronic lab notebook (ELN)/LIMS solution is a digital replacement for paper notebooks, and there was a 30% increase in productivity in adoption, which was adopted by more than 6,000 scientists. Additionally, the rising efforts of clinicians and pathologists to provide the best and error-free results are contributing to the increasing demand for laboratory informatics products and services, which is further influencing the market in a positive manner.
However, the lack of integration standards for laboratory informatics and the lack of skilled professionals are restraining the overall market growth.
The COVID 19 has raised pressure on testing procedures, taking time and innovation into consideration to combat the pandemic situation. Thus, the traditional laboratory procedures are required to upgrade in terms of managing the entire operations. This may influence the demand of the LIMS. The LIMS has shown possible ways to get fast approval in regulatory workflow from the FDA due to its capabilities of reporting results. As per FDA and CDC guidelines, the CloudLIMS has already helped multiple labs less than a week using FDA-approved, preconfigured workflows.
As time is a key factor in pandemics to controlling rising cases, thus, LIMS platforms are robust to track and monitor the laboratory information. Companies, like lab advantage solutions, have developed LabVantage COVID-19 LIMS. This platform helps manage and accelerate the laboratory workflow in less than four weeks through its inbuilt capabilities.
Moreover, in the product segment of the laboratory informatics market, laboratory information management system is believed to have the largest market size.
A Laboratory Information Management System (LIMS) enables efficient management of the flow of samples and associated data to improve lab efficiency. LIMS are usually intended for the laboratories having recurring workflows, such as quality control laboratories. LIM system contains a special data structure, and the processes of the laboratory (workflow) should already be established in a certain format. LIMS products have been losing market share to electronic lab notebooks (ELN) and laboratory execution systems (LES) in recent years. This trend can be observed in the sales growth of LES vendors and the investment of large LIMS providers in the field of ELN and LES. Some of the major players in the market studied, such as LabVantage Solutions Inc., have invested heavily to develop comprehensive and highly integrated LES and ELN capabilities.
Moreover, Laboratory information management systems are being increasingly integrated into biobanking. These systems allow effective management and tracking of data quality, end-user billing, patient demographics, and security. For example, CloudLIMS is a purpose-built, scalable, SaaS, in the cloud LIMS and grows with its biorepository by supporting automation, data management, and regulatory requirements. They also improve data sampling and research information integration, thereby, making data access easier. Additionally, market players are focusing on the launch of new LIMS across the Globe to enhance their market presence. In July 2020, LabVantage Solutions launched edition 8.5 of its lab information management system (LIMS) with a fully integrated scientific data management system (SDMS). Thus, due to the above mentioned factors, the laboratory information management system segment will contribute significantly to the market growth.
The United States is the most COVID-affected country across the world. In the COVID-19 pandemic, the need for data sharing across various platforms and with patients has become essential. Data from diagnostic centers to hospitals to confirmed positive patients must flow as freely as possible without sacrificing privacy or other essential elements of ethical care and research. Hence, in the United States, healthcare providers focus on digital Information systems to keep track of the total tests administered, treatment results, evolving case definitions, and streamline many other processes. Thus, the COVID-19 outbreak is more likely to increase the utilization and adoption of laboratory informatics systems now and in the future.
North America currently dominates the market for laboratory informatics and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the well-established healthcare industry and better reimbursement facilities in the region. The United States holds the majority of the market in the North American region due to the higher adoption of digital healthcare in the country and rising investments done by the companies over there.
Furthermore, in the United States, the geriatric population is growing at a high rate, and these populations are associated with several diseases. Thus, the increasing number of lifestyle disorders may ultimately grow the demand for laboratory tests. These laboratory systems help in improve efficiencies.
Several companies are launching products, services, and initiatives associated with laboratory informatics. For example, in March 2020, Ovation.io announced an initiative to double the COVID-19 testing capacity across the United States. In this initiative, the company delivers cloud technology to help labs serve patients and gather public health data. Hence this permits the clinicians to quickly access results and reports, leading to faster diagnosis and treatment.
The laboratory informatics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. Companies, like Abbott Laboratories (Abbott Informatics Corporation), Agilent Technologies, McKesson Corporation, and Thermo Fischer Scientific Inc., hold substantial shares in the market.